The ADA recommends that a comprehensive oral evaluation be carried out on all patients about to begin therapy with oral bisphosphonates (or as soon as possible after beginning therapy), and that patients on these drugs be educated on maintaining oral hygiene, which is the best way to prevent oral diseases that may require dental surgery.
The ADA notes that dentists, generally, will not need to modify dental treatments based solely on oral bisphosphonate therapy. Further, patients should understand that the risk for developing osteonecrosis of the jaw is considered very small and that the vast majority of patients taking an oral bisphosphonate do not develop any oral complication.
Source: Eureka Alert